NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma
Source: Onclive, December 2024
NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
The United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) has recommended funding for tebentafusp-tebn (Kimmtrak) through England’s National Health Service (NHS) for eligible patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
This recommendation is consistent with the marketing authorization for tebentafusp and reverses the initial negative recommendation made by NICE in May 2023. At that time, NICE acknowledged that tebentafusp met the criteria for a life-extending treatment and was likely to improve survival.2 However, the organization justified the decision by citing uncertainties in the most likely cost-effectiveness estimates, noting they exceeded acceptable thresholds for NHS resource allocation for end-of-life treatments.